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Antibiotic drug resistance among hospital and
community acquired methicillin resistant Staphylo-
coccus aureus (MRSA) has dramatically eroded the
efficacy of current therapeutics.Wedescribe a chem-
ical genetic strategy using antisense interference to
broadly identify new drug targets that potentiate
the effects of existing antibiotics against both etio-
logical classes of MRSA infection. Further, we
describe the resulting chemical genetic interaction
networks and highlight the prominent and overlap-
ping target sets that restore MRSA susceptibility to
penicillin, cephalosporins, and carbapenems. Phar-
macological validation of this approach is the potent
synergy between a known inhibitor to a member of
this genetic potentiation network (GlmS) and a broad
set of b-lactam antibiotics against methicillin resis-
tant Staphylococci. Developing drug-like leads to
these targets may serve as rational and effective
combination agents when paired with existing b-lac-
tam antibiotics to restore their efficacy against
MRSA.INTRODUCTION
Staphylococcus aureus is the leading Gram-positive bacterial
pathogen causing both hospital and community-acquired infec-
tions and for which antibiotic treatment options are compro-
mised by emerging drug resistance. Methicillin resistant
S. aureus (MRSA), which is highly cross resistant to essentially
all other b-lactam antibiotics, now represents over half of all
S. aureus clinical isolates identified in the USA (Styers et al.,
2006). In fact, the number of serious infections caused by
MRSA alone in the United States as monitored in 2005
approached nearly 95,000 cases, of which almost 19,000 related
fatalities were estimated. Consequently, mortality associated
with MRSA infection now exceeds those attributed to HIV/
AIDS in the United States (Klevens et al., 2007; Bancroft, 2007).Chemistry & Biology 18, 1379–138Despite the growing resistance to b-lactam antibiotics across
both Gram-positive and Gram-negative bacterial pathogens,
they remain the single most clinically relevant antibiotic drug
class (Walsh, 2003). Mechanistically, b-lactams acetylate an
essential transpeptidation activity common to a family of peni-
cillin binding proteins (PBPs), thereby inhibiting peptidoglycan
crosslinking and integrity of the cell wall (van Heijenoort, 2001).
The key resistance determinant to these agents is an acquired
gene, mecA, which encodes a penicillin binding protein
(PBP2A) with markedly reduced affinity to b-lactams compared
to native S. aureus PBPs (Matsuhashi et al., 1986; Song et al.,
1987; de Lencastre et al., 2007). MRSA resistance to b-lactams
is achieved by the cooperative function of PBP2A and PBP2,
which provide transpeptidation and transglycosylation activities,
respectively, necessary to crosslink peptidoglycan precursors
and construct the cell wall under conditions when other suscep-
tible PBPs are otherwise inactivated by these agents (Pinho
et al., 2001a; Scheffers and Pinho, 2005).
PBP2A and PBP2 represent important antibiotic targets that
may be exploited to develop new efficacious agents against
MRSA (Pinho et al., 2001b; Moya´ et al., 2010). However,
a growing number of auxiliary genes have also been identified
by transposon-based screens that are typically involved in pepti-
doglycan precursor biosynthesis and turnover and are required
for PBP2A-mediated b-lactam resistance. (de Lencastre and
Tomasz, 1994; Berger-Ba¨chi and Rohrer, 2002; de Lencastre
et al., 1999; Sobral et al., 2003; Gardete et al., 2004). Additional
studies also emphasize an emerging network of genetic pertur-
bations capable of potentiating the effects of b-lactams against
MRSA (Pinho and Errington, 2003; Memmi et al., 2008; Kuroda
et al., 2003; Gardete et al., 2006; Beltramini et al., 2009).
Recently, we identified SAV1754 as a new member of this auxil-
iary gene set that is required for peptidoglycan biosynthesis and
whose cognate inhibitors display potent synergy in combination
with b-lactams (Huber et al., 2009). Therefore, further genetic
characterization of the b-lactam resistance of MRSA, combined
with the identification of inhibitory compounds to members of
this b-lactam genetic potentiation network provide a rational
framework for discovering combination agents potentially effec-
tive in restoring b-lactam activity against MRSA.
Here we describe a S. aureus antisense interference-based
screen of 245 essential genes in the hospital and community-
acquired clinical isolates MRSA COL and USA300 to genetically9, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1379
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Figure 1. Antisense Induction ofmecA (Pbp2A) and Restored MRSA
COL Susceptibility to Imipenem
(A) Schematic of antisense interference and relationship between antisense
induction and protein depletion as a function of xylose induction level.
(B) Example of restored susceptibility of MRSA COL to imipenem by xylose
inducible antisense depletion of mecA. MRSA COL are seeded in agar
chambers with varying concentrations of xylose (0 mM, right, to 100 mM, left),
and imipenem are spotted horizontally at three concentrations. The increase in
xylose concentration results in increasing susceptibility of MRSA COL to
imipenem due to depletion of Pbp2A protein by antisense interference.
See also Table S1.
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b-Lactam Resistance by MRSAidentify additional auxiliary factors, which if partially depleted,
enhance MRSA susceptibility to b-lactams or other clinically
used antibiotics. Demonstrating the reliability of this approach,
several previously described auxiliary genes including murE,
femX (fmhB), femD (glmM), pbp2, SAV1220, and SAV1754
were faithfully identified to restore b-lactam susceptibility of
both MRSA strain backgrounds (Memmi et al., 2008; Berger-
Ba¨chi and Rohrer, 2002; Gardete et al., 2004; Beltramini et al.,
2009; Huber et al., 2009). Additional essential genes involved
in peptidoglycan precursor synthesis that share this phenotype
by antisense modulation include the majority of the mur and
pbp genes, albeit to differing extents among different b-lactam
antibiotic classes. Genes not previously known to affect MRSA
b-lactam susceptibility were also identified, including those
involved in cell division (ftsZ, ftsW, and ftsA), wall teichoic acid
biosynthesis (tarL), secretion (spsB), transcription (hu), and
SAV1892; the latter of which is largely uncharacterized but
predicted to participate in cell wall biogenesis or remodeling.
Here, the resulting chemical genetic interaction networks are
described for antibiotics targeting S. aureus cell wall, DNA
synthesis and replication, RNA biogenesis, fatty acid biosyn-
thesis, and protein synthesis. The utility of these genetic
potentiation maps is that target-specific inhibitors to antibiotic
susceptibility determinants should phenocopy their genetic
inactivation. Consistent with this, we demonstrate potent
synergy between a previously described GlmS inhibitor, Nva-
FMDP (Chmara et al., 1998), and a broad set of b-lactam antibi-
otics against MRSA and methicillin resistant Staphylococcus
epidermidis, MRSE.
RESULTS
Antisense-Mediated Genetic Depletion and Antibiotic
Hypersusceptibility Screening
Clinically relevant antibiotics used in the study were selected ac-
cording to their microbiological activity against an extensive
panel of current S. aureus clinical isolates. (Fritsche et al.,
2008). These include the b-lactam antibiotics whose activity
has been most extensively eroded by commonly occurring
MRSA isolates, such as the penicillin/b-lactamase combination
agent, piperacillin-tazobactam, cephalosporins (cefepime, cef-
tazidime, and ceftriaxone), and carbapenems (imipenem and
ertapenem). Other clinically used antibiotics selected for this
study include fluoroquinolones that target DNA replication
(ciprofloxacin and levofloxacin), protein synthesis inhibitors
(tetracycline, linezolid, and azithromycin), as well as the mecha-
nistically distinct agents, trimethoprim, (DNA synthesis), rifam-
picin (RNA biogenesis), and cerulenin (fatty acid biosynthesis).
Three early stage antibacterial leads, all targeting SAV1754,
were also selected for study (Huber et al., 2009).
To genetically screenMRSA for altered sensitivity to the above
antibiotics, we transformed COL strain with individual members
of a previously described plasmid library (Donald et al., 2009)
containing xylose inducible antisense interference fragments
specifically targeting one of 245 S. aureus essential genes.
Briefly, the library was constructed by subcloning short anti-
sense fragments (ranging in size from 200 to 800 bp in length)
behind the pT5X xylose inducible promoter (Forsyth et al.,
2002). Upon xylose addition into the growth medium, antisense1380 Chemistry & Biology 18, 1379–1389, November 23, 2011 ª2011expression targets the complementary mRNA, leading to tran-
scription and translation interference of the target protein (For-
syth et al., 2002; Donald et al., 2009; Xu et al., 2010). Although
full xylose induction leads to growth arrest, partial antisense
induction affords titratable knockdown of gene expression to
sensitize cells to antibiotics (Donald et al., 2009) (Figure 1). As
an attempt to normalize genetic knockdown across all targets,
a subminimal inhibitory concentration (MIC) of the inducer was
determined so that growth was routinely impaired 10%–20%
(IC10-IC20) for each antisense strain. Antibiotic hypersensitivity
screens were performed by seeding individual COL-AS (anti-
sense) strains in LB medium containing suitable xylose levels
to partially knockdown target expression (10–50 mM depending
on strain) and spotting 10 ml of each antibiotic on the plate.
Target-specific hypersensitivities were identified by comparing
the antibiotic zone of inhibition of antisense knockdown strains
in the presence versus absence of xylose. Qualitative antibiotic
hypersensitivity scores were assigned to AS strains as being
strong (3+), medium (2+), mild (1+), or lacking a phenotype (0+)
(Figure 2; see Table S1 available online).
Consistent with the reliability of the screen to detect target-
based antibiotic hypersensitivity, a number of known drug-target
interactions were identified (Figures 2A and 2B). These include
the dfrA-AS strain (3+), depleted of dihydrofolate reductase,
and which specifically displayed a pronounced hypersensitivity
to its known inhibitor, trimethoprim (Walsh, 2003). The AS strain
corresponding to thyA (thymidylate synthase) also displayed
detectable (1+) and specific hypersensitivity to trimethoprim,
consistent with the observed synergy between trimethoprim
and sulfonamides, the latter of which targets dihydropteroateElsevier Ltd All rights reserved
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Figure 2. MRSACOLChemical Genetic Interaction
Map by Antisense Interference
(A)MRSACOLchemical genetic interactionmapof noncell
wall antibiotics. Chemical genetic interactions are de-
picted as connecting lines between genes (blue circle) and
antibiotics (green squares). Lines are colored according to
qualitative scores assigned for the level of hypersensitivity
between compound and target gene as red (3+, strong),
orange (2+, medium), blue (1+, mild), or dashed black
(0+, no hypersensitivity despite expectation a phenotype
wouldbeobserved). Antibiotics tested include levofloxacin
(Levo), ciprofloxacin (Cipro), cerulenin (Cer), azithromycin
(Azi), trimethoprim (Tri), and linezolid (Lin).
(B) Representative hypersensitization phenotypes of
members of the noncell wall antibiotic set. COL antisense
bearing strains were seeded in LB agar plates supple-
mented with 50 mM xylose to induce modest antisense
expression (top row) or without xylose (bottom row) that
serves as negative control for gene-specific hypersus-
ceptibility phenotypes. Representative chemical genetic
qualitative scores are shown.
(C) COL genetic potentiation map of cell wall antibiotics.
Chemical genetic interactions are depicted as described
in (A). Antibiotics tested include imipenem (Imi), ertape-
nem (Ert), cefepime (Cef), ceftazidime (Ceftra), ceftriaxone
(Ceftri), piperacillin/tazobactam (PipT), vancomycin (Van),
and the SAV1754 inhibitors, DMPI, CDFI, and compound
D (CmpdD).
(D) Representative qualitative scores for cefepime
hypersusceptibility was performed as described in (B),
using antisense strains corresponding to the known
auxiliary genes reported to contribute to b-lactam
susceptibility; fmhB (3+), murE (2+), and glmM (1+). Note,
murZ (0+) is used as a negative control based on the
presence of a functional paralog, murA, which buffers the
effect of a mild depletion of murZ.
See also Figures S2, S3, and S4 and Table S1.
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b-Lactam Resistance by MRSAsynthase and leads to the incorporation into dead end tetrahy-
drofolate analogs (Walsh, 2003). Striking and specific hypersen-
sitivity was also detected between the pbp2A-AS strain (3+) andChemistry & Biology 18, 1379–1389, November 23,all six b-lactams tested, as expected based
on the essential role PBP2A performs in
b-lactam resistance (Figure 2C). Similarly, the
SAV1754-AS strain displayed marked hyper-
sensitivity (2+) to cognate inhibitors, DMPI,
CDFI, and compound D (Huber et al., 2009).
Further, rpoB and rplK AS strains (both 3+) as
well as rpsS-AS (2+) and rpsB-AS (1+) revealed
a range of antibiotic hypersensitivities, specifi-
cally against the protein synthesis inhibitors
linezolid and azithromycin, respectively. Target
or mechanism-based hypersensitivity, albeit
mild, was also detected in screens using cipro-
floxacin (recR-AS (1+), parC-AS (1+)) and
levofloxicin (parC AS (1+)), as well as cerulenin
(fabI-AS (1+), fabF-AS (1+)). Screening b-lactam
antibiotics revealed several fem or auxiliary (aux)
genes previously reported to participate in
MRSA resistance to these agents, including
femX (fmhB), femD (glmM), femF (murE), and
pbp2 (Figures 2C and 2D). In all but one case,(glmM-AS; 1+), the corresponding AS strains displayed strong
hypersusceptibility (3+) to both imipenem and ertapenem, as
well as multiple penicillins and cephalosporins. Reciprocally,2011 ª2011 Elsevier Ltd All rights reserved 1381
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b-Lactam Resistance by MRSAinactivation of pbp3 is reported to not significantly alter
MRSA b-lactam susceptibility (Pinho et al., 2000), consistent
with our findings (Pbp3-AS; 0+). Collectively these results
demonstrate that relevant xylose concentrations were used
to appropriately sensitize AS strains broadly across antibi-
otic screening conditions to identify known target-pathway-
antibiotic interactions.
Antisense-Based Genetic Potentiation of b-Lactams
Mild AS depletion in COL identifies multiple well characterized
S. aureus genes required for b-lactam resistance (Figure 2C;
Table S1). Functionally, these genes can be grouped to five
general cellular processes. Group 1 members include GlmS
(3+ across all b-lactams tested), a glucosamine-6-phosphate
synthase involved in the first committed step in peptidoglycan
precursor synthesis, as well as MurA-G and MraY, which partic-
ipate in eight sequential steps starting with UDP-GlcNAc to build
the peptidoglycanmonomer also known asmurein pentapeptide
or lipid II (van Heijenoort, 2001) (Figure 3). Interestingly, murB,
murC, andmurE AS strains displayed reproducibly strong hyper-
sensitization (3+) across all six b-lactams whereas murA, murD,
murF, mraY, and murG-AS strains all displayed only mild to
moderate sensitization specifically to imipenem, ertapenem,
and cefepime. Group 2 members include SAV1754 and the
pbp gene family. Remarkably, SAV1754-AS strain hypersuscep-
tibility to all b-lactams is restored to levels comparable to that of
the pbp2A-AS strain (3+), whereas the pbp3-AS strain was unal-
tered in its hypersensitivity to these agents. Interestingly, pbp1
and pbp2-AS strains displayed a reciprocal relationship in their
b-lactam hypersensitivity to these agents, with the pbp2-AS
strain preferentially strongly susceptible to imipenem and
ertapenem, whereas pbp1-AS produced only moderate suscep-
tibility to carbapenems but strong resensitization to all cephalo-
sporins tested (Figures 2B and 4A). Group 3 genes include
ftsA, ftsW, and ftsZ, and encode core components of a macro-
molecular complex (termed the Z ring) that is required for
coordinating cell division and the position of the resulting division
plane, processes that directly affect peptidoglycan synthesis
and septum formation (Adams and Errington, 2009). Indeed,
AS strains corresponding to each of these Z-ring components
displayed strong and largely identical hypersusceptibility (3+)
to all b-lactams except piperacillin-tazobactam (Figures 2C
and 4B).
Group 4 genes participate in diverse cellular processes. For
example, glyS encodes a glycyl tRNA synthetase; the glyS-AS
strain is uniquely and strongly hypersensitive (3+) to the full set
of b-lactams tested. Although perhaps counterintuitive, these
results corroborate biochemical studies that demonstrate
a charged glycyl tRNA synthetase serves as an essential
substrate donor of Fem proteins to reconstitute in vitro pentagly-
cine bridge synthesis (Schneider et al., 2004). Modest depletion
of TarL (an essential enzyme involved in wall teichoic acid
synthesis) also resensitizes MRSA to all b-lactams, although to
varying extents (1–3+) (Figure 4C). These results are corrobo-
rated by a recent report that deletion of the first committed
step in this pathway (tarO) also dramatically resensitizes
MRSA to this family of antibiotics (Campbell et al., 2011). We
speculate that the mild phenotypes associated with spsB-AS
may relate to the established function of spsB, a signal pepti-1382 Chemistry & Biology 18, 1379–1389, November 23, 2011 ª2011dase required for signal peptide cleavage of cell wall localized
proteins (Cregg et al., 1996) and which is transcriptionally
induced by b-lactam mediated cell wall damage (Gardete
et al., 2006). Likewise, a homolog to the histone-like protein,
hu, has been reported to localize in the cell wall and control
cell wall assembly in Mycobacterium smegmatis (Katsube
et al., 2007). Mild depletion of hu by antisense induction resulted
in considerable hypersusceptibility (2–3+); particularly to carba-
penems (Figure 4C).
Group 5 genes are predicted to participate in cell wall biogen-
esis and are represented by SAV1891, SAV1892, and SAV1220.
Whereas the AS strain corresponding to SAV1892 produced
robust hypersensitivity (3+) to all b-lactams, SAV1891-AS
displayed intermediate and varied b-lactam sensitivities,
whereas the SAV1220-AS strain sensitivity to each of these
agents was mild (Figure 4C). SAV1220 has recently been
demonstrated to function as a serine/threonine kinase of a
phospho relay signal transduction pathway critical for maintain-
ing proper cell wall architecture (Beltramini et al., 2009). Interest-
ingly, SAV1892 is structurally related to UDP-N-acetylmuramyl
tripeptide synthetase-like proteins, including MurF and Mpl
whereas SAV1891 is predicted to encode a cobyric acid syn-
thase. SAV1891 and SAV1892 are predicted to be coexpressed
from a common operon. Based on SAV1892 similarity to MurF,
which we demonstrate shares this b-lactam hypersusceptibility
phenotype, as well as the reported hypersensitivity of the Acine-
tobacter baylyi mpl mutant to b-lactams (Gomez and Neyfakh,
2006), we favor the hypothesis that SAV1892 functions directly
in cell wall biogenesis, whereas antisense interference of
SAV1891 likely mediates these phenotypes by polar effects on
upstream expression of SAV1892.
Extending the Identification of Genetic Potentiators
to b-Lactams in the Community-Acquired MRSA
Strain USA300
Essential genes that when partially depleted display a conserved
b-lactam hypersusceptibility phenotype in both hospital and
community acquired MRSA clinical isolates represent a privi-
leged set of b-lactam potentiation targets. Accordingly, anti-
sense interference plasmids corresponding to genes with
demonstrated b-lactam hypersensitivity in MRSA COL were
shuttled into the community acquired MRSA strain, USA300,
a highly virulent and intrinsically antibiotic resistant and epidemic
strain common in the United States (David and Daum, 2010).
USA300 antisense containing strains were evaluated for altered
susceptibility to the following subset of antibiotics; imipenem,
penicillin, cefepime, cerulenin, vancomycin, ceftriaxone, trimeth-
oprim, linezolid, and ciprofloxacin. Generally, a strong corre-
lation was observed between the specific antibiotic hypersus-
ceptibility phenotypes by genetic depletion performed in COL
versus USA300 (Figure 5; Table S1). In particular, murB, murC,
glyS, SAV1754, pbpA, pbp2A, and ftsZ-AS strains all displayed
dramatically restored USA300 susceptibility (3+) specific to the
representative penicillin, cephalosporins, and cerbapenem
tested. We also observe that murA, murD, murG, mraY, and
spsB appear to preferentially affect USA300 susceptibility
(all 2–3+ with respect to these antibiotics) versus that detected
in COL. These results demonstrate that reproducible b-lactam
hypersusceptibility phenotypes are achieved by antisenseElsevier Ltd All rights reserved
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Figure 3. Schematic Representation of Coordinated Cell Wall Biosynthesis and Cell Division in S. Aureus
Peptidoglycan synthesis starts in the cytoplasm with the conversion of fructose-6-P to UDP-N-acetyl-glucosamine (UDP-GlcNAc) by GlmS, GlmM, and GlmU
enzymes. The final soluble precursor, UDP-MurNAc-pentapeptide (UDP-MurNAc) is produced by the sequential action of the MurA to MurF enzymes. Lipid I
(undecaprenylphosphate-MurNAc-pentapeptide) is formed at the membrane by MraY, which transfers the soluble UDP- MurNAc-pentapeptide to
undecaprenylphosphate (C55-P). MurG links UDP-GlcNAc to lipid I, producing lipid II (undecaprenylphosphate-GlcNAc-MurNAc-pentapeptide). Lipid II is further
modified in S. aureus, by the addition of 5 glycine residues, catalyzed by FemXAB enzymes; such interpeptide bridges occur in most Gram-positive bacteria, but
may vary in composition and length. Finally, lipid II is translocated across themembrane by an unknownmechanism, of which both SAV1754 and FtsW have been
proposed. Extracellular peptidoglycan units are incorporated into the nascent peptidoglycan network through the activity of PBPs by transglycosylation (TG) and
transpeptidation (TP) reactions.
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b-Lactam Resistance by MRSAknockdown of Group 1–5 genes in USA300. Further, the resulting
gene set defines a genetic potentiation map of targets for which
compound-specific inhibitors are predicted to synergize with
b-lactams against hospital and community-acquired MRSA.Chemistry & Biology 18, 1379–138Synergistic Chemical-Chemical Interactions between
b-Lactam Antibiotics and GlmS Inhibitor, Nva-FMDP
To investigate whether our genetic findings could be confirmed
pharmacologically, we examined the growth inhibitory effects9, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1383
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Figure 4. Representative Hypersusceptibility
Phenotypes of Members of the Cell Wall Genetic
Potentiation Map
(A) PBP hypersusceptibility of antisense bearing strains to
pbpA (top left), pbp2 (top right), pbp3 (middle left), and
pbp2A (middle right) under partial antisense induction
(plus 50 mM xylose) versus the negative control, pbp2-AS
(bottom left) assayed identically but without antisense
induction (minus xylose). Antibiotics are spotted according
to grid coordinates (bottom right).
(B) Cell division (Fts) hypersusceptibility of antisense
bearing strains to ftsZ (top left), ftsA (top right), and ftsW
(bottom left) under partial antisense induction (plus 50 mM
xylose) versus the negative control, ftsW-AS assayed
identically but without antisense induction (bottom right).
(C) Antisense bearing strains corresponding to tarL (top
left), SAV1892 (top right), and hu (bottom left) under partial
antisense induction (plus 50 mM xylose) versus the
negative control, tarL-AS assayed identically but without
antisense induction (bottom right).
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b-Lactam Resistance by MRSAand potential synergistic activity of Nva-FMDP (Chmara et al.,
1998) in combination with distinct b-lactam antibiotic classes
and clinically relevant Staphylococci. Nva-FMDP (whose bioac-
tive pharmacophore is an analog of glutamine) is a competitive
inhibitor of GlmS, the first committed step in peptidoglycan
synthesis in S. aureus (Komatsuzawa et al., 2004). GlmS uses
glutamine as an ammonia source to convert D-fructose-6-phos-
phate into D-glucosamine 6-phosphate, which is subsequently
converted by GlmM and GlmU to UDP-N-acetylglucosamine,
the fundamental amino sugar building block of peptidoglycan
(van Heijenoort, 2001). Although Nva-FMDP displays potent
whole cell activity against Bacillus subtilis (Chmara et al., 1998)
and S. epidermidis (Figure S1), S. aureus growth is largely unaf-
fected by the compound (Figure 6A; Figure S1). This likely reflects
species-specific differences between permease and protease-
specific import and activation mechanisms required for Nva-
FMDPbioactivity (Chmara et al., 1998). Nva-FMDPdoes however1384 Chemistry & Biology 18, 1379–1389, November 23, 2011 ª2011 Elsevier Ltd All rstrongly potentiate imipenem activity against
MRSA COL (Figure 6A; Figure S1). Moreover,
potentiation between Nva-FMDP and imipenem
is fully suppressed by supplementing 20 mM
N-acetylglucosamine (GlcNAc) into the medium,
demonstrating the target-specific inhibitory
effect of Nva-FMDP (Figure 6B). Further, modest
depletion of GlmS by antisense induction mark-
edly increases MRSA COL sensitivity to Nva-
FMDP, recapitulates the chemical genetic
hypersensitivity to imipenem, and enhances the
potentiating effect of these agents in a GlcNAc-
suppressible manner (Figures 6C and 6D).
Analogous conclusions are drawn by targeting
folate biosynthesis using dfrA-AS, trimethoprim,
sulfamethoxazole, and thymidine supplementa-
tion to suppress inactivation of the pathway (Fig-
ure S1B and Supplemental Information).
Antibiotic synergy is routinely determined by
standard checkerboard methodology using
a 64-point dose matrix and is formally definedas a fractional inhibitory concentration index (FICI)%0.5, where
the FICI is the sum of the fractional inhibitory concentrations
(FIC) of each compound (Amsterdam, 2005). Accordingly, we
quantified the observed potentiation between these agents
against MRSA COL, USA300, and methicillin resistant Staphylo-
coccus epidermidis (MRSE). Nva-FMDP and imipenem produce
FICI values of 0.08 and 0.02 against MRSA COL and MRSE
respectively, with up to 256-fold reduced levels of imipenem
being required to inhibit growth when combined with Nva-
FMDP (Figure 6E; Table S2). Although USA300 is intrinsically
resistant to b-lactam antibiotics, its imipenem susceptibility is
cell density dependent (this is referred to as an inoculum effect;
see Sabath et al., 1975). Under such high inoculum conditions,
significant synergy in combination with Nva-FMDP (FIC1 0.19)
is also observed (Figure 6E; Table S2). Interestingly, Nva-
FMDP mediated potentiation is not restricted to imipenem but
extensively demonstrated among a broad set of b-lactamights reserved
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Figure 5. USA300 Genetic Potentiation Map of Cell Wall Antibiotics
(A) Chemical genetic interactions are depicted as described in Figure 2.
(B) Antisense bearing strains corresponding to ftsZ (top left), tarL (top right), and spsB (bottom left) under partial antisense induction (plus 50 mM xylose) versus
the negative control (USA300 maintaining the antisense vector without antisense interference fragment) assayed identically in the presence of optimized xylose
concentrations (12.5–50 mM).
Chemistry & Biology
b-Lactam Resistance by MRSAantibiotics tested, including additional cabapenems (ertape-
nem), cephalosporins (cefepime, ceftriaxone, and ceftazidime),
and penicillin G (Figure S1). Therefore, these chemical-chemical
interactions underscore a mechanism-based potentiation
strategy to restore b-lactam antibiotic activity broadly against
methicillin resistant Staphylococci, as originally predicted by
our chemical genetic interaction map.
DISCUSSION
Chemical genetic interaction networks, albeit historically re-
stricted to nonessential genes, provide important mechanistic
insights into how model microbes tolerate antibiotic stressChemistry & Biology 18, 1379–138(Gomez and Neyfakh, 2006; Girgis et al., 2009; Barker et al.,
2010; Costanzo et al., 2010). Here we describe an antisense
interference-based genetic knock down strategy to identify
essential genes that are required for the maintenance of
b-lactam antibiotic resistance among clinical isolates of
S. aureus. Beyond previously described auxiliary genes, multiple
well characterized genes not previously demonstrated to
participate in MRSA b-lactam susceptibility, including multiple
genes involved in peptidoglycan and wall teichoic acid glycopol-
ymer synthesis, protein synthesis, cell division, transcription,
and signal transduction were identified to similarly and strongly
reset susceptibility of MRSA to b-lactams in hospital and
community-acquired MRSA clinical isolates. The extent of the9, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1385
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Figure 6. Synergistic Activity between Nva-FMDP and
b-Lactam Antibiotics
(A) Nva-FMDP (256 mg) and imipenem (3 mg) spotted separately or
co-spotted on COL seeded plate reveals potentiation between the
two agents.
(B) Same as (A) but with 20mMGlcNAc supplemented to the plate.
(C) COL glmS-AS strain under partial antisense induction (20 mM
xylose) confers prominent hypersensitivity to Nva-FMDP and
imipenem; enhanced potentiation is observed by co-spotting
these agents.
(D) Same as (C) but with 20 mM GlcNAc supplemented to the
plate.
(E) Nva-FMDP and imipenem checkerboard assays against COL,
USA300, and MRSE. FIC of each antibiotic pair are plotted.
Synergism is achieved with combinations of the two agents fully
inhibiting growth with individual FIC values yielding a sum FICI of
%0.5 (indicated by the black diagonal line). USA300 b-lactam
susceptibility is inoculum dependent; accordingly checkerboard
assays were performed under standard (13) inoculum cell density
and 103 normal cell density.
See also Figure S1 and Table S2.
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b-Lactam Resistance by MRSAb-lactam potentiating gene network we describe likely reflects
our focus on screening essential genes through conditional
expression, thereby overcoming the intrinsic difficulty of identi-
fying such phenotypes among essential genes by previous
transposon-based strategies (de Lencastre and Tomasz, 1994;
de Lencastre et al., 1999; Berger-Ba¨chi and Rohrer, 2002).
Importantly, these results predict that small molecules that inter-
dict gene products comprising the b-lactam genetic potentiation
maps should synergize the effects of b-lactams against drug
resistant Staphylococci. Accordingly, we provide pharmacolog-
ical validation that the GlmS inhibitor Nva-FMDP is a remarkably
effective synergist in combination with a broad set of b-lactams,
restoring the efficacy of this antibiotic class well below their clin-
ically defined drug resistance breakpoint concentrations against
MRSA and MRSE clinical isolates. In addition, the interdicting
compound does not need to fully abrogate the activity of its
cognate target to be an effective synergist to b-lactams, as
demonstrated by themodest knock down levels (IC10-IC20) using
antisense interference against essential genes to hypersensitize
MRSA to such antibiotics. Further, MRSA strains are viable in the
presence of Nva-FMDP at concentrations that achieve strong
b-lactam synergy (Figure 6A). This phenomenon may be
extended to future studies to identify low potency compounds1386 Chemistry & Biology 18, 1379–1389, November 23, 2011 ª2011 Elsevier Lthat only partially inactivate the target gene or possibly
even nonessential genes but are still effective in
restoring b-lactam susceptibility against MRSA or
other bacterial pathogens (Tamae et al., 2008).
We postulate that as a consequence of the adapted
mechanism of b-lactam resistance that MRSA has
acquired, it is highly vulnerable to genetic potentiation
of this drug class over non-b-lactam antibiotic drug
classes. This vulnerability reflects a network of cellular
processes that are indirectly required to maintain the
residual activity of PBP2 transglycosidase and
PBP2A transpeptidase function under b-lactam stress,
and that if breached, dramatically exacerbate the
effects of these antibiotics (Figure 3). For example,
FtsZ is required for proper localization of PBP2 to thedivision site to mediate localized peptidoglycan synthesis,
peptidoglycan cross linking, and septum formation (Pinho and
Errington, 2003). Therefore, under conditions where PBP2 may
be partially mislocalized from its normal site of action, it is
reasonable to expect that the resulting MRSA strain would be
hypersensitized to b-lactam antibiotics, as we demonstrate.
Extending this view, as the Z ring is a multisubunit complex,
depletion of other components (e.g., FtsA and FtsW) of the
complex may phenocopy FtsZ b-lactam hypersensitivity. Pinho
and colleagues have also demonstrated that normal PBP2 local-
ization to the septum is achieved by binding to its peptidoglycan
monomer substrate, which itself is synthesized at sites of
nascent cell wall synthesis (Pinho and Errington, 2005). Conse-
quently, depletion of peptidoglycan precursor synthesis by
genetic knockdown of elements of this pathway as early as
glmS could adversely affect PBP2 localization and confer b-lac-
tam hypersensitivity of these MRSA strains. Localization of other
PBPs is also affected in the context of specific genetic muta-
tions. Recently, normal septum localization of PBP4 has been
demonstrated to be dependent on TarO, the first committed
enzymatic step required for the production of the cell wall glyco-
polymer, wall teichoic acid (Atilano et al., 2010). These results,
combined with the recent demonstration that tarO deletiontd All rights reserved
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2011), likely explain the observed hypersusceptibility phenotype
of tarL to these agents. However, in addition to PBP mislocaliza-
tion as a mechanism for elevated b-lactam susceptibility, alter-
native possibilities exist. These include the possible transcrip-
tional repression of PBPs, as demonstrated by murE depletion
resulting in reduced transcription of both pbp2A and pbp2
(Gardete et al., 2004). Importantly, these PBP defects need not
be mutually exclusive and in fact may be exacerbated by deple-
tion of peptidoglycan polymer levels below those which are
required for viability resulting from the combined effects of
disrupting peptidoglycan synthesis by chemical and genetic
means at multiple points within the pathway.
Interestingly, in MRSA COL, PBPs display unique hypersensi-
tivities among distinct b-lactam antibiotic classes. For example,
modest antisense induction targeting pbp2-AS strain results in
marked hypersensitivity to carbapenems, whereas pbpA-AS
strain is reciprocally hypersensitive to cephalosporins. Further,
pbp3-AS strain lacks hypersensitivity to all b-lactams, as previ-
ously reported (Pinho et al., 2000) whereas pbp2A-AS strain is
hypersensitive to all b-lactams tested. As pbp2A provides the
molecular basis for MRSA resistance to b-lactams (Matsuhashi
et al., 1986; Song et al., 1987; de Lencastre et al., 2007), its
genetic depletion is expected to confer pan-hypersensitivity to
these agents. However, the basis for the hypersensitivity profiles
of the remaining PBPs is unclear. One possibility is that carbape-
nems preferentially inhibit PBP2 whereas cephalosporins
possess greater affinity to the pbpA encoded PBP1, recapitu-
lating that demonstrated for their Pseudomonas aeruginosa
PBP orthologs (Moya´ et al., 2010 and references therein). Alter-
natively, these phenotypes may manifest as a direct result of
their distinct functional roles in S. aureus peptidoglycan biosyn-
thesis, in combination with genetic interactions between indi-
vidual PBP members as well as their distinct binding affinities
to different b-lactams.
Genetic potentiation maps also highlight an important limita-
tion of target based screening approaches that rely on genetic
knockdown of a target to hypersensitize cells to cognate inhibi-
tors. Indeed, this approach can be successful, as demonstrated
by the prominent target-specific hypersensitivity of glmS-AS to
Nva-FMDP (Figures 6C and 6D) as well as the discovery of pla-
tensimycin (Wang et al., 2006). However, our results highlight
an alternative outcome; one in which chemical hypersensitivity
need not directly reflect the chemical inhibition of the depleted
target, but instead hypersensitivity resulting from genetic deple-
tion of a member of the genetic interaction network of the target
that is chemically inhibited. The broad b-lactam hypersensitivity
as demonstrated among peptidoglycan, cell division, and other
pathways indirectly affecting PBP function underscores this
potential complexity. Further, the hypersensitivity phenotype of
a target to its cognate inhibitor (e.g., SAV1754-DMPI, CDFI, or
Compound D) may also be markedly less pronounced than the
target’s hypersensitivity to compounds that do not directly target
it, such as b-lactams (Figures S2 and S3). Similarly, PBP2A
displays pan-hypersusceptibility to all b-lactams tested, yet the
protein has poor affinity and is not inhibited by these agents.
Therefore, chemical hypersensitivity of a strain genetically
depleted for a particular target is, on its own, insufficient to
surmise compound mode of action and requires independentChemistry & Biology 18, 1379–138genetic and/or biochemical confirmation. Despite this potential
complexity, antisense knockdown strains with particular antibi-
otic susceptibilities serve as potential whole cell screening
assays for inhibitors of particular pathways comprising the
genetic interaction network of a given target (see Supplemental
Information for details).
Recently, an elegant genetic proof-of-concept of the achiev-
able efficacy that combination agents could provide in treating
b-lactam resistant S. aureus infections has been demonstrated
(Jo et al., 2011). Deletion of the nonessential vraSR two compo-
nent signal transduction pathway restores b-lactam suscepti-
bility to a broad collection of MRSA isolates (Kuroda et al.,
2003; Gardete et al., 2006; Jo et al., 2011). Jo et al. (2011) extend
these results and demonstrate that deletion of the vraSR operon
also restored the efficacy of oxacillin in murine models of MRSA
USA300 pneumonia and skin infection (Kalan and Wright, 2011).
b-lactam genetic potentiation maps therefore provide an impor-
tant first step to discovering target-specific inhibitors that, if
coadministered, coformulated, or chemically linked to existing
b-lactams, provide a rational strategy to restoring the efficacy
of this important class of antibiotic drugs against drug resistant
Staphylococci.
SIGNIFICANCE
Antibiotic drug resistance, as has emerged among hospital
and community acquired methicillin resistant Staphylo-
coccus aureus (MRSA), has dramatically eroded the efficacy
of current therapeutic agents and created an urgent need for
new treatment options. We describe an antisense interfer-
ence strategy to modulate essential gene function in this
important bacterial pathogen and identify genes required
for MRSA resistance to b-lactams. In total, 245 essential
genes are screened under partially repressing conditions
in the hospital-acquired MRSA isolate COL for altered
susceptibility to 17 clinically relevant antibiotics. We
describe an extensive chemical genetic interaction network
of b-lactam hypersensitivity determinants that contribute to
b-lactam resistance of MRSA. Members of this network
include genes known or predicted to be principally involved
in various aspects of cell wall and cell division processes,
including peptidoglycan synthesis (glm, mur, pbp), cell wall
signaling (SAV1220), cell division (fts), and genes of
unknown function (SAV1892). Further, we demonstrate the
requirement of this genetic potentiation network for b-lac-
tam resistance of the community-acquired MRSA epidemic
strain, USA300. Recapitulating these genetic findings,
a small molecule inhibitor of the earliest step in peptido-
glycan biosynthesis (achieved using the GlmS inhibitor,
Nva-FMDP), dramatically potentiates the activity of several
b-lactam antibiotics against these MRSA strains as well as
methicillin resistant Staphylococcus epidermidis. In so
doing, we provide a rational framework for developing inhib-
itors of targets within this chemical genetic interaction
network, which if paired with existing b-lactam antibiotics
would display synergistic antibacterial activity against
methicillin resistant Staphylococci and offer a combination
agent strategy to restore the efficacy of this important anti-
biotic drug class. More broadly, this approach is generally9, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1387
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b-Lactam Resistance by MRSAapplicable to other microbial pathogens and antibiotics as
well as cancer cell lines and anticancer agents in which
synergistic agents for combination therapy are sought.
EXPERIMENTAL PROCEDURES
S. Aureus Strains, Antisense Interference Plasmids,
and Synergy Studies
All studies utilize MRSA COL (MB 5393), USA300 (MB 6256) or MRSE strain
MB6255. A detailed description of all antisense interference fragments,
including DNA sequence, BLAST scores of best S. aureus match, and gene
nomenclature in MSSA strain RN4220, MRSA COL, and USA300 is provided
(Table S3). COL and USA300 were transformed with antisense interference
plasmids or vector control as previously described (Huber et al., 2009). Assay
plates were prepared by seeding 107 cells/ml of each culture into 48C cooled
LB Miller agar containing 34 mg/ml chloramphenicol, and 0, 25, 50, 100, or
200 mM xylose. Agar plates were allowed to set and then spotted with 10 ml
of each drug and incubated at 37C with humidity for 18 hr. Qualitative scores
of all chemical genetic interactions summarized in Figures 2, 3, 4, and 5 are
provided (Table S1). The qualitative hypersensitivity scores are based on visual
inspection of zone of inhibition of xylosed induced plate versus uninduced
plate. A score of (0) is given when no differential zone sizes are observed
between the plates, and a score of 1 or 2 is given when differential zone sizes
are at least 2-fold greater when compared to the uninduced plate with a score
of 3 given zone differential >4-fold. Plate photos of antibiotic zone of inhibition
for all confirmed chemical genetic interactions in MRSA COL and USA300,
including relevant controls, is provided as searchable pdfs (Figures S3 and
S4). The checkerboard technique was used to quantify synergy between
antibiotic agents (Amsterdam, 2005). FICI values were determined by adding
the FIC value of each compound required to achieve a MIC when paired
with the second agent. As Nva-FMDP is inactive against COL, Nva-FMDP
FIC values are based on the assumption that its MIC would be two times the
highest concentration (32.8 mg/ml) used in the checkerboard assay.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
doi:10.1016/j.chembiol.2011.08.015.
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